SARS CoV 2 News and Research

RSS

Study shows how human cells fight viral infections with the emergence of SARS-CoV-2

Science's pursuits of unraveling how human cells fight viral infections kicked into high gear in 2020 with the devastating emergence of the SARS-CoV-2 virus.

30 Sep 2020

A TLR2 agonist reduces SARS-CoV-2 in upper respiratory tract of ferret model

In a recent bioRxiv* preprint paper, Professor Miles W. Carroll et al. study an agonist for reducing the SARS-CoV-2's viral load. They show that prophylactic intra-nasal administration of TLR2/6 (toll-like receptor) agonist, INNA-051, reduces viral RNA in the nose and throat, in a ferret model.

30 Sep 2020

Different triggers for Kawasaki disease suggest slightly different genetic susceptibilities

Researchers at University of California San Diego report that while Kawasaki disease (KD) occurs in clusters, the traits, and thus the triggers of the inflammatory disease vary among clusters. The findings are published in the September 2020 online issue of The Journal of Pediatrics.

30 Sep 2020

Researchers develop research model to understand the impact of coronavirus on lungs

Scientists at Boston University's National Emerging Infectious Diseases Laboratories (NEIDL) and the Center for Regenerative Medicine (CReM) joined forces to develop the most relevant research model possible for understanding how the coronavirus virus impacts the lungs, by engineering living, "breathing" human lung cells from stem cells for the task.

30 Sep 2020

Abacus Diagnostica's new multiplex assay provides reliable influenza, COVID-19 diagnosis in 75 minutes

Abacus Diagnostica is a small Finnish company developing and manufacturing assays and devices for rapid molecular diagnostics. Since the beginning of COVID-19 outbreak the company has worked decisively on the development of SARS-CoV-2 diagnostics.

30 Sep 2020

Sleep apnea increases risk of severe COVID 19

Coronavirus disease (COVID-19) is a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A subset of COVID-19 patients face a severe form of the disease with hospitalization, respiratory failure, or death. Severe COVID-19 is primarily characterized by respiratory distress, and the common risk factors are older age, obesity, cardiovascular disease, diabetes, and poor lung function.

29 Sep 2020

College football crowds could impact COVID-19 spread

The observed increase in COVID-19 cases coinciding with the reopening of college campuses all over the US has drawn intense scientific attention. A recent paper, by Washington State University researchers, published on the preprint server medRxiv* in September 2020 reports that this threat is directly linked to the holding of in-person sporting events on these campuses.

29 Sep 2020

New graphical tool to identify potent neutralizing antibodies against SARS-CoV-2

A new study by researchers at the Indian Institute of Science and the University of Queensland and published on the preprint server medRxiv in September 2020 discusses using a novel tool to identify the most effective among currently known anti-SARS-CoV-2 NAbs.

29 Sep 2020

Using new technology to study antibody responses in SARS-CoV-2-infected individuals

Using a technology called VirScan to study coronavirus antibody responses in a large cohort of SARS-CoV-2-infected and control individuals, researchers identified epitopes recognized by a large fraction of COVID-19 patients, epitopes cross-reactive with antibodies developed in response to other human coronaviruses, and 10 epitopes likely recognized by neutralizing antibodies.

29 Sep 2020

Ventilation systems may increase the risk of exposure to novel coronavirus

Ventilation systems in many modern office buildings, which are designed to keep temperatures comfortable and increase energy efficiency, may increase the risk of exposure to the coronavirus, particularly during the coming winter, according to research published in the Journal of Fluid Mechanics.

29 Sep 2020

Australian scientists develop a nasal spray that could stop SARS-CoV-2 infection

The novel product, called INNA-051, is being developed by Ena Respiratory, and laboratory experiments have shown that it reduced viral replication by as much as 96 percent in the animal study. Spearheaded by Public Health England’s (PHE) Deputy Director, Professor Miles Carroll, the new study described the potential treatment and has been published in the open-source preprint server bioRxiv*.

29 Sep 2020

Common cold in the past may provide some protection from COVID-19

Seasonal colds are by all accounts no fun, but new research suggests the colds you've had in the past may provide some protection from COVID-19.

29 Sep 2020

Case fatality rates for COVID-19 and health indicators

Researchers from Turkey and Switzerland collaborated to study the nation-specific case fatality rates for COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The pandemic has affected around 33.5 million people worldwide and killed over 1 million making it one of the largest global health crises in recent memory.

29 Sep 2020

A study contradicting the phenotypical relationship between plasmablasts and developing neutrophils

A team of scientists from Australia challenges the findings of a recent study by Wilk et al. demonstrating that plasmablasts transdifferentiate into developing neutrophils in severe coronavirus disease 2019 (COVID-19). The Australian study is currently available on the bioRxiv preprint server.

29 Sep 2020

Self-collection of blood for COVID-19 antibody testing may be a reliable and easy alternative

Some evidence suggests that IgGs appear at 6-15 days after infection and may persist for months. However, large-scale testing over time is required to understand the immunological response to COVID-19 with greater accuracy. A recent pilot study published on the preprint server medRxiv in September 2020 reports the use of self-collected capillary blood for serology, with highly promising results.

29 Sep 2020

SARS-CoV-2 infects human embryonic epithelial and lung cells

As COVID-19 continues to spread the world over, investigators are still trying to understand how it ravages the human body. A recent study published on the preprint server bioRxiv in September 2020 shows that the virus is capable of infecting human embryonic cells that are destined to form the epithelial surfaces of the body, both internal and external, as well as lung cells.

29 Sep 2020

Qatar worker communities may have attained herd immunity against SARS-CoV-2

Now, a recent study published on the preprint server medRxiv* in September 2020 shows the achievement of herd immunity for SARS-CoV-2 infection by at least some expatriate worker communities in Qatar.

29 Sep 2020

Discovery of specific kinase as a novel drug target against SARS-CoV-2 and other coronaviruses

By using a modern genome-wide knockout approach to single out coronavirus host factors in human cells, researchers from Rega Institute in Belgium discovered a potential new target that might be exploited for developing drugs against the ongoing coronavirus disease (COVID-19) pandemic, but also future outbreaks of highly pathogenic coronaviruses

29 Sep 2020

UC researchers find potential treatment that could be applied to COVID-19

By examining preexisting research for other conditions, researchers at the University of Cincinnati have found a potential treatment that could be applied to COVID-19.

29 Sep 2020

Naturally occurring enzyme holds potential as low-cost therapeutic to treat COVID-19

Researchers from UCLA and China have found that catalase, a naturally occurring enzyme, holds potential as a low-cost therapeutic drug to treat COVID-19 symptoms and suppress the replication of coronavirus inside the body.

29 Sep 2020

SARS CoV 2 News and Research

Study shows how human cells fight viral infections with the emergence of SARS-CoV-2

A TLR2 agonist reduces SARS-CoV-2 in upper respiratory tract of ferret model

Different triggers for Kawasaki disease suggest slightly different genetic susceptibilities

Researchers develop research model to understand the impact of coronavirus on lungs

Abacus Diagnostica's new multiplex assay provides reliable influenza, COVID-19 diagnosis in 75 minutes

Sleep apnea increases risk of severe COVID 19

College football crowds could impact COVID-19 spread

New graphical tool to identify potent neutralizing antibodies against SARS-CoV-2

Using new technology to study antibody responses in SARS-CoV-2-infected individuals

Ventilation systems may increase the risk of exposure to novel coronavirus

Australian scientists develop a nasal spray that could stop SARS-CoV-2 infection

Common cold in the past may provide some protection from COVID-19

Case fatality rates for COVID-19 and health indicators

A study contradicting the phenotypical relationship between plasmablasts and developing neutrophils

Self-collection of blood for COVID-19 antibody testing may be a reliable and easy alternative

SARS-CoV-2 infects human embryonic epithelial and lung cells

Qatar worker communities may have attained herd immunity against SARS-CoV-2

Discovery of specific kinase as a novel drug target against SARS-CoV-2 and other coronaviruses

UC researchers find potential treatment that could be applied to COVID-19

Naturally occurring enzyme holds potential as low-cost therapeutic to treat COVID-19

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News